EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor: Results of a 28-day Phase 1b Study in NUC suppressed CHB Patients
EDP-514, a Novel Pangenotypic Class II Hepatitis B Virus Core Inhibitor Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients
EDP-514, a Novel Pangeonotypic Class II Hepatitis B Virus Core Inhibitor: Preliminary Results of a 28-Day Phase 1b Study in NUC-Suppressed CHB Patients
EDP-514, a Potent Pangenotypic Class II Hepatitis B Virus Core Inhibitor, Demonstrates Significant HBV DNA and HBV RNA Reductions in a Phase 1b Study in Viremic, Chronic Hepatitis B Infected Patients
EDP-514, a Novel Pan genotypic Class II Hepatitis B Virus Core Inhibitor: Final Results of a Phase 1 Study in Healthy Adult Subjects